-+ 0.00%
-+ 0.00%
-+ 0.00%

Ganli Pharmaceutical announced that its wholly-owned subsidiary Ganli Pharmaceutical Shandong Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration on the GLR1044 injection, and agreed to conduct clinical trials for the treatment of moderate to severe atopic dermatitis in adults. This product is a biosimilar of dupriumab. As of September 30, 2025, the company has invested a total of 657.24,500 yuan in R&D expenses in this project. Currently, only the original manufacturer Sanofi's dupliumab injection has been approved for marketing in China, and its global sales in 2024 will be 13.072 billion euros.

Zhitongcaijing·12/08/2025 10:41:07
Listen to the news
Ganli Pharmaceutical announced that its wholly-owned subsidiary Ganli Pharmaceutical Shandong Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration on the GLR1044 injection, and agreed to conduct clinical trials for the treatment of moderate to severe atopic dermatitis in adults. This product is a biosimilar of dupriumab. As of September 30, 2025, the company has invested a total of 657.24,500 yuan in R&D expenses in this project. Currently, only the original manufacturer Sanofi's dupliumab injection has been approved for marketing in China, and its global sales in 2024 will be 13.072 billion euros.